Table 2 DNAm estimated cumulative lead exposure and PD risk
From: DNA methylation biomarker for cumulative lead exposure is associated with Parkinson’s disease
SGPD (n = 1889) | PEG (n = 807) | Meta-analysis | Test of study heterogeneity | ||||||
|---|---|---|---|---|---|---|---|---|---|
OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | Q | p-value | ||
MODEL 1 | DNAm Tibia-lead | 2.06 (1.66, 2.56) | 5.4E−11 | 1.60 (1.20, 2.15) | 0.001 | 1.89 (1.59, 2.24) | 8.09E−13 | 1.32 | 0.25 |
MODEL 2 | 1.54 (1.22, 1.95) | 2.8E−04 | 1.48 (1.03, 2.13) | 0.019 | 1.52 (1.25, 1.86) | 2.84E−05 | 1.87 | 0.17 | |
MODEL 1 | DNAm Patella-lead | 0.59 (0.45, 0.78) | 1.6E−04 | 1.19 (0.82, 1.73) | 0.356 | No replication (study heterogeneity) | 8.83 | 0.003 | |
MODEL 2 | 0.70 (0.53, 0.93) | 0.015 | 1.18 (0.80, 1.75) | 0.417 | 7.53 | 0.006 | |||